Melanotan I (Afamelanotide) Research: What Published Studies Have Investigated

What is Melanotan I?

What is Melanotan I? It is a synthetic linear tridecapeptide analogue of α-melanocyte-stimulating hormone (α-MSH), carrying two deliberate substitutions on the native sequence. In the medicinal-chemistry literature it is written [Nle⁴, D-Phe⁷]-α-MSH and abbreviated NDP-α-MSH or NDP-MSH. Its international non-proprietary name is afamelanotide.

The two substitutions are the entire design. Native α-MSH is a 13-residue peptide that is rapidly degraded — the methionine at position 4 is oxidation-prone and the phenylalanine at position 7 sits at a site vulnerable to proteolysis. Replacing methionine-4 with norleucine removes the oxidisable sulfur; replacing L-phenylalanine-7 with its D-enantiomer makes the neighbouring bonds far harder for proteases to cleave. Two changes, one linear chain, and a molecule that in the 1980 report showed the “ultralong biological activity” of its title.

Because Melanotan I and Melanotan-2 are constantly conflated online, the distinction belongs at the top rather than buried below: MT-I is linear and full-length; MT-II is cyclic and shortened. They are not the same molecule with different doses. They are not the same molecule at all.

Discovery and origin in the literature

Arizona, 1980

The founding paper is Sawyer, Sanfilippo, Hruby and colleagues, Proceedings of the National Academy of Sciences, 1980 (PMID 6777774): “4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity”. It came out of the α-melanotropin structure-activity programme at the University of Arizona built around Victor Hruby and Mac Hadley — the same programme that a decade later produced the cyclic lactam analogues including Melanotan-2 (Al-Obeidi and colleagues, 1989, PMID 2555512).

NDP-α-MSH became, and remains, the standard high-potency reference agonist in melanocortin pharmacology. A great deal of what is known about melanocortin receptor binding was established using it as the benchmark ligand, which is why it appears in receptor papers that have nothing to do with its later clinical career.

Receptor mapping in the 1990s

Once the melanocortin receptors were cloned, NDP-α-MSH became the tool for characterising them. Frändberg and colleagues (1994, PMID 8060302) reported evidence for alternate points of attachment for α-MSH and its [Nle⁴, D-Phe⁷] stereoisomer at the melanocortin-1 receptor — that is, the D-Phe substitution does not merely stabilise the peptide, it changes how it sits in the binding pocket. Yang, Dickinson, Haskell-Luevano and Gantz (1997, Journal of Biological Chemistry, PMID 9287296) went further and mapped the molecular basis of the NDP-α-MSH interaction with the human MC1R.

A rare disease finds a use for it

The clinical turn came from erythropoietic protoporphyria (EPP), a rare inherited photodermatosis in which patients experience severe pain on light exposure. Minder (2010, Expert Opinion on Investigational Drugs, PMID 21073357) set out the investigational case for afamelanotide in EPP dermal phototoxicity. That programme is what turned a 1980 laboratory peptide into a licensed product thirty-nine years later.

Reference data

Values from the public chemical record (PubChem CID 16197727). Identity and physical form only.

Note the contrast with the sibling compound: Melanotan-2 is a cyclic heptapeptide closed by an Asp-Lys lactam bridge, a smaller and conformationally constrained molecule. Different length, different topology, different mass. No reconstitution procedure, quantity or route is given or implied anywhere on this page.

Mechanisms researchers have examined

The Melanotan I mechanism literature is receptor pharmacology and photobiology. Each point below is what studies characterise in defined systems:

• Melanocortin-receptor agonism, MC1R-led — the clinical-pharmacology literature describes afamelanotide as a first-in-class MC1R agonist (Kim and Garnock-Jones, 2016, PMID 26979527). NDP-α-MSH is a high-potency agonist and is used as the reference ligand across the melanocortin receptor family; its clinical development is built specifically on the MC1R arm.
• The conserved His-Phe-Arg-Trp message sequence — melanocortin peptides share this central recognition motif, and the D-Phe substitution sits inside it. Frändberg and colleagues (1994) reported that the substitution alters the attachment geometry at MC1R rather than simply protecting the peptide.
• Eumelanin synthesis in melanocytes — MC1R activation couples to cAMP and the eumelanin-synthesis programme in melanocyte models. This is the mechanistic pathway examined in the photobiology work; it is described here as receptor and cell signalling, not as a cosmetic outcome.
• Metabolic stability by design — the norleucine and D-phenylalanine substitutions were introduced to resist oxidation and proteolysis, and the 1980 paper reports the resulting prolonged activity in the melanotropin bioassays of the period.
• Controlled-release formulation in clinical use — the approved product is a biodegradable subcutaneous implant containing 16 mg (Kim and Garnock-Jones, 2016). Formulation is a pharmaceutical fact about a licensed product, stated for accuracy; it is not guidance and does not apply to research material.

Research findings by area

The phase 3 programme in erythropoietic protoporphyria

Langendonk and colleagues (2015, New England Journal of Medicine, PMID 26132941) reported two multicentre, randomised, double-blind, placebo-controlled trials of subcutaneous implants containing 16 mg of afamelanotide. Seventy-four patients in the European Union and ninety-four in the United States were randomised 1:1 to afamelanotide or placebo every 60 days — five implants in the EU study, three in the US study, over 180-day and 270-day study periods respectively. The primary efficacy endpoint was the number of hours of direct sunlight exposure without pain; type and duration of sun exposure, number and severity of phototoxic reactions and adverse events were recorded, quality of life was assessed with validated questionnaires, and a subgroup of US patients underwent photoprovocation testing.

An NEJM-published pair of placebo-controlled randomised trials is a substantially stronger form of evidence than anything supporting most compounds in this catalogue, and it is why afamelanotide reached approval. It is reported here as the trial record for a licensed medicine in a specific rare disease — not as anything transferable to any other context.

Reviews and the post-approval record

Kim and Garnock-Jones (2016, PMID 26979527) reviewed the clinical efficacy, tolerability and pharmacological properties in EPP, describing the phase 3 trial CUV039 and noting headache and implant-site reactions among commonly occurring adverse reactions. Wensink and colleagues (2021, Expert Review of Clinical Pharmacology, PMID 33507118) reviewed the compound for prevention of phototoxicity in EPP with the benefit of post-approval experience. Rhodes (2024, British Journal of Dermatology, PMID 38736212) examined vitamin D status in EPP patients taking afamelanotide — the kind of downstream question that only arises once a drug is genuinely in long-term use.

Regulatory status, stated precisely

Afamelanotide is marketed as SCENESSE and is approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria. Kim and Garnock-Jones (2016) record the European Union approval; Resnik and colleagues (2023, Journal of Drugs in Dermatology, PMID 37683058) record that it was approved in the United States in 2019. Two clarifications belong immediately alongside that: the approval is narrow, covering one rare disease and one indication; and Cellworks does not supply the approved product. Research-grade Melanotan I is a laboratory reagent supplied for research use only, and the existence of a licensed medicine containing the same peptide does not make a research reagent a medicine.

Research models and evidence status

Melanotan I versus Melanotan-2, side by side

The two compounds diverge on every axis worth naming. Structure: MT-I is a linear 13-residue chain with norleucine-4 and D-phenylalanine-7; MT-II is a cyclic heptapeptide closed by a lactam bridge. Development: MT-I went through two randomised placebo-controlled phase 3 trials and holds marketing approval in the EU and US for one rare disease; MT-II’s human record is a small early pilot study and it has no approval anywhere. Literature: MT-I’s later literature is clinical trials and post-approval pharmacology; MT-II’s later literature is dominated by case reports documenting safety signals with unlicensed use. The Melanotan-2 page covers that record and this page does not restate it.

What is not established

Everything outside the approved indication. The phase 3 evidence concerns erythropoietic protoporphyria and nothing else; no randomised trial has examined this peptide for any other purpose, and the trials used a controlled-release pharmaceutical implant manufactured to medicinal standards under a study protocol — which is a different thing from a lyophilized research reagent in every respect that matters. The long-term melanocortin pharmacology of chronic MC1R agonism outside a monitored patient population is not characterised. And the melanocortin-family safety-signal literature discussed on the Melanotan-2 page is not answered by this compound’s approval; a narrow licence in a rare disease under specialist supervision does not generalise.

This page makes no efficacy, therapeutic, cosmetic, photoprotective or other use claim of any kind. It reports the trial record for a licensed medicine and the chemistry of a research peptide, and keeps those two things separate. The material catalogued here is supplied for laboratory research use only — not for human or veterinary use.

How to verify this compound yourself

Melanotan I’s two design substitutions are exactly what a certificate of analysis has to prove, and they are analytically awkward in different ways:

• D-phenylalanine at position 7 is invisible to mass spectrometry — D- and L-phenylalanine have identical masses. A chain built with L-Phe at position 7 is the native-configuration peptide, a different molecule with different stability, and it will pass a mass check and an ordinary HPLC purity assay. Chiral analysis, or documented synthesis using the D-amino-acid building block, is what settles it. This is the single most important verification question for MT-I.
• Norleucine versus methionine at position 4 — this substitution is mass-visible: norleucine and methionine differ by the sulfur atom. An observed mass matching ≈ 1646.8 Da is consistent with the norleucine peptide; a mass consistent with the methionine-containing native analogue is a different compound.
• Terminal modifications — the peptide is N-acetylated and C-amidated. A free-acid C-terminus differs by roughly one mass unit from the amide, a small difference that high-resolution mass spectrometry resolves and low-resolution instruments may not.
• Tryptophan and light sensitivity — the tryptophan in the message sequence is photo-labile and oxidisable, which is why storage protected from light matters and why oxidation products can appear as late-eluting HPLC peaks.
• HPLC purity and counter-ion — reversed-phase chromatography separates full-length product from deletion sequences; the counter-ion, usually trifluoroacetate, affects net peptide content per unit mass and should be documented.

See how to read a COA for what each certificate line means, and how to verify peptide purity for how the methods fit together. The exact batch received can be checked on the self-serve verify tool.

Research-grade sourcing and verification

Melanotan I is not held in stock. It appears on our sourcing catalogue as available to order — our supplier lists it, we have not bought it, and material of this kind typically takes about two to three weeks to reach us. For laboratory research use only, it is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, verifiable at the lot level. For the cyclic lactam sibling and its very different record, see Melanotan-2 research; for the separately developed melanocortin agonist bremelanotide, see PT-141 research. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. “4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity.” Proceedings of the National Academy of Sciences USA. 1980;77(10):5754–5758. PMID 6777774. pubmed.ncbi.nlm.nih.gov/6777774.
2. Yang YK, Dickinson C, Haskell-Luevano C, Gantz I. “Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor.” Journal of Biological Chemistry. 1997;272(37):23000–23010. PMID 9287296. pubmed.ncbi.nlm.nih.gov/9287296.
3. Frändberg PA, Muceniece R, Prusis P, Wikberg J, Chhajlani V. “Evidence for alternate points of attachment for α-MSH and its stereoisomer [Nle4, D-Phe7]-α-MSH at the melanocortin-1 receptor.” Biochemical and Biophysical Research Communications. 1994;202(3):1266–1271. PMID 8060302. pubmed.ncbi.nlm.nih.gov/8060302.
4. Minder EI. “Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.” Expert Opinion on Investigational Drugs. 2010;19(12):1591–1602. PMID 21073357. pubmed.ncbi.nlm.nih.gov/21073357.
5. Langendonk JG, Balwani M, Anderson KE, et al. “Afamelanotide for Erythropoietic Protoporphyria.” New England Journal of Medicine. 2015;373(1):48–59. PMID 26132941. pubmed.ncbi.nlm.nih.gov/26132941.
6. Kim ES, Garnock-Jones KP. “Afamelanotide: A Review in Erythropoietic Protoporphyria.” American Journal of Clinical Dermatology. 2016;17(2):179–185. PMID 26979527. pubmed.ncbi.nlm.nih.gov/26979527.
7. Resnik SR, Targett D, Resnik BI. “Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States.” Journal of Drugs in Dermatology. 2023;22(9):941–949. PMID 37683058. pubmed.ncbi.nlm.nih.gov/37683058.
8. Wensink D, Wagenmakers MAEM, Langendonk JG. “Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.” Expert Review of Clinical Pharmacology. 2021;14(2):151–160. PMID 33507118. pubmed.ncbi.nlm.nih.gov/33507118.
9. Rhodes LE. “Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide.” British Journal of Dermatology. 2024;191(3):317–318. PMID 38736212. pubmed.ncbi.nlm.nih.gov/38736212.
10. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. “Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics.” Journal of Medicinal Chemistry. 1989;32(12):2555–2561. PMID 2555512. pubmed.ncbi.nlm.nih.gov/2555512 (cited for the Melanotan-2 structural contrast).
11. National Center for Biotechnology Information. “PubChem Compound Summary for CID 16197727, Afamelanotide.” pubchem.ncbi.nlm.nih.gov/compound/16197727 (formula, mass, CAS 75921-69-6).